Information Library
Market Access
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Award Winning Poster at ISPOR EU
November 17, 2009
Pascale Peeters' award winning poster presented at ISPOR EU 2009 in Paris. -
Rewarding Innovation and Value: What is the Role of Comparative Effectiveness Research
October 6, 2009
The impact of comparative effectiveness research on the future of drug development. -
Patient Outcomes and Health Economics
September 25, 2009
Across Europe the impetus to measure patient outcomes and demonstrate positive health economic benefits is intensifying. Jacco Keja, Managing Director and Practice Leader at Quintiles Consulting, visiting Professor Life Sciences Pricing, Erasmus University, looks at the emerging opportunities for pharma companies within this environment. -
Patient Management
September 25, 2009
Knowing how patients are responding to your drug in everyday life can unlock your brand’s market potential. From outcomes to proof of efficacy, real-world patient data can help support market access, payer reimbursement and — most important — help prescribers improve patient treatment and adherence. Through an exclusive partnership with Apollo Medical Systems, Innovex UK has developed a patient management data service that reports the real impact of your brand in the context of total patient management, quickly and cost-effectively. -
Comparative Effectiveness Research as a Drug Development Tool
September 1, 2009
A Q&A with John Doyle, Vice President and Practice Leader of Quintiles Consulting, sheds light on the complex issue of comparative effectiveness research, and its strategic importance in successful and efficient biopharmaceutical development. -
For Investigors: Market Situation
July 17, 2009
Learn about the clinical trial market situation. -
Orphan Drugs in the U.S.
June 24, 2009
Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009(International Society for Pharmacoeconomics and Outcomes Research) on “Orphan Drugs' Market Access in the U.S.” -
Effects of NICE HTA on Drug Prescribing and Expenditures in the U.S.
June 24, 2009
Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009 (International Society for Pharmacoeconomics and Outcomes Research) on “The Effects of NICE HTA on Drug Prescribing and Expenditures in the U.S.” -
Poised for success
June 16, 2009
Learn how a holistic life cycle approach can improve your commercial organization's productivity and flexibility -
Harnessing a Speciality Salesforce
March 26, 2009
NovaQuest’s predecessor, PharmaBio Development, committed more than $400 million in milestone payments and sales force services to fund the launch of Cymbalta and support commercialization efforts for five years. A dedicated service company created by PharmaBio Development is providing more than 500 Innovex sales representatives to supplement the extensive Lilly primary care and specialty sales forces.